Medical News Today -
9 Sep 2013 11:00
The Lancet Oncology has published findings from a study, which showed that the new oral therapy IMNOVID® - (pomalidomide), used in combination with low-dose dexamethasone demonstrated a significant survival advantage over high-dose dexamethasone alone, in patients with relapsed and refractory multiple myeloma (rrMM).[1] "Unfortunately the prognosis for relapsed and refractory multiple myeloma is poor as there are few effective therapeutic options for people living with this disease" said Profes...
Share this Article